Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
earthling has been a very LTH and has filtered many (including me) and appears to get over involved at times. he/she had to take a "rest" sometime ago so lets leave him/her alone to calm down. I'm not invested now but look in now and again. Good luck to the stalwarts on this board
apologies for spelling of unnecessary - had a senior moment. hope I've got it right this time.
is this listed on the nyse/nasdaq as it belongs to an Italian group which is not a PLC. thanks. I ask the question because I wonder if it really is necessary for us to do so bearing in mind this is a niche product where a) there probably isn't a single oncology centre, research or front line, which is not aware of this product and b)with a steady income of revenue spiked by new FDA approvals and research reports any requirement to raise revenue for more R&D should be a doddle. I would therefore suggest that the annual subscription fee for listing which is currently in the region of $40K is unnessesary. gla
to see this board and sp come alive again after months in the doldrum.
the £1 barrier sure is a tough nut to crack!
oilhead - there is nothing to think about - Angle would NOT be expanding their facilities if they thought there was any doubt getting FDA approval
This is posted from memory which is not improving so apologise for any errors. FDA is divided into two sections drugs and everything else and are situated in different locations The every thing else section has an 800 odd workforce I believe. To my way of thinking we should fit into this category i.e there are no side effects for the fda to consider, it is safe to use and the question of which drugs to use is down to the local clinicians not angle. Therefore the FDA only has to decide is if pasortix is more beneficial than existing procedures and does it do what is claimed on the tin. I would have thought that the trials would have contained
separate reports on the efficiency of this little beauty backed up by the main reports. So I am optpmistic that we may have the result late January/ early Feb.
I do not foresee any acceptable bid for angle prior to FDA approval - but it could well be that a pharma company or two might wish to start building a stake in angle prior to approval which would definately help the SP. Its a funny old game we are in - a couple of successful trials and the SP soars to 80p and now we are approaching the pay off the SP is flat as a pancake.
Cheers Bermuda - the interesting point in his chat is that all other companies in competition require samples to be sent away whereas Pasortix can be done in house - another big PLUS.
The entry level for NASDAQ is I believe $4 a share held over 2 years so to this novice it would make sense to have a consolidation of the shares in the region of 10:1 as early as possible. Anyone any thoughts on this. An increase to 60p in the coming week would definately be welcome to cut my paper losses to very nearly break even! GLA
I fully agree with you olderandwiser - it is disconcerting to say the least. There are many companies both private and public in this field of operations and I feel time is of the essence. Failure to meet the timeline for FDA submission for the second time will certainly not help and that is down to management not the workforce who have probably been working their cotton socks off.
you are quite correct agl confirmed this was indeed a dnaCT trial - diasappointing - will explain the fall yesterday.
papers today are full of news on liqiud biopsy for breast cancer- have emailed company to confirm pasortix was involved as would have expected an RNS but there again LSE may be at fault if an RNS has been issued.
Good for you BOJO - but don't overstretch yourself - I held a "dead cert" during the dot com bubble where the share went from pennies to £20 + with talk of a listing on NASDAQ only for it to end up in liquidation not too many months later!!
appear to be the only day when buys outstrip the sells........ one day Rodney........
Interesting info on FDA site -Providing Angle meet their deadline I am confident we will have a good prezzy at chrimble. It used to take up to 12 YEARS to get approval for a drug now they hope to do it in 6 months - for medical devices looking at their lists it could be two months.
Interesting info on FDA site -Providing Angle meet their deadline I am confident we will have a good prezzy at chrimble. It used to take up to 12 YEARS to get approval for a drug now they hope to do it in 6 months - for medical devices looking at their lists it could be two months.
There is some quite disparate messaging going on on this board as to the subject and I hope the board spells it out in clear and concise language at the AGM this week.
Cheers Jelenko - That is why they have put what is probably the toughest one first.
The last set of results stated that the first application to the FDA would be for metamastic breast cancer. A question I would like to put to the board is how do you see the other applications being submitted, will they also be single applications or a possible "job lot"? If single are we talking the proverbial 6 months for each?